Par Pharmaceutical To Present At 2006 UBS Global Specialty Pharmaceuticals Conference
Posted on: Tuesday, 18 April 2006, 15:00 CDT
SPRING VALLEY, N.Y., April 18 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. will be presenting at the 2006 UBS Global Specialty Pharmaceuticals Conference on Tuesday, April 25, at 11:00 am EDT at The Grand Hyatt New York.
The audio-only live webcast will be accessible through the UBS website at http://www.ibb.ubs.com/ or through the Par Pharmaceutical website at http://www.parpharm.com/. A replay will be available at the same link address until May 25, 2006, and will begin 3 hours after the presentation.
Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. In 2005, Par received approval for and introduced Megace(R) ES, its first branded pharmaceutical product, and expects to launch its second in 2006. Par's Generic Products Division is committed to providing high-quality pharmaceuticals that are affordable and accessible to patients. Par manufactures, markets or licenses more than 110 generic drugs. For press release and other company information, visit http://www.parpharm.com/
Par Pharmaceutical Companies, Inc.
CONTACT: Stephen J. Mock, or Cecelia C. Heer, both of Par PharmaceuticalCompanies, Inc., +1-201-802-4000
Web site: http://www.parpharm.com/
Source: PRNewswire-FirstCall
Related Articles
- Solvay Pharmaceuticals, Inc. And Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
- Momenta Pharmaceuticals to Present At the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
- Elite Pharmaceuticals Appoints a Prominent Specialty Pharmaceutical Executive, Dr. Veerappan Subramanian, to Its Board of Directors and Engages Dr. Subramanian As Strategic Advisor
- AVANIR Pharmaceuticals Invites Investors to Listen to the 2006 UBS Global Life Sciences Conference Webcast
- CardioVascular BioTherapeutics to Present at 2006 UBS Life Sciences Conference
- Research and Markets: Vodafone Australia Is 100% Owned By Vodafone Group Plc And Is The Third Largest Mobile Carrier In Australia - 2006 Australia - Telco Company Profiles - 2nd Tier Companies
- Idera Pharmaceuticals Announces 2006 Financial Results for the Three and Six Months Ended June 30, 2006; Recent Highlights Include Expanded TLR Programs and Additional Funding
- Alnylam to Webcast Presentation at the Bank of America 2006 Specialty Pharmaceuticals Conference
- Research and Markets: Vodafone Australia Provides Mobile Services to 2.7 Million Customers, Representing an 18% Market Share: 2005-2006 - Australia - Telco Company Profiles
 |
 |
User Comments (0)
RSS Feeds